Health
Health News
OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses
OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses PR Newswire INDIANAPOLIS,...
Read moreAntengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021
Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021 PR Newswire SHANGHAI and HONG...
Read moreAntengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021
Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021 PR Newswire SHANGHAI and HONG KONG, June...
Read moreAmgen to Webcast Investor Meeting at ASCO 2021
Amgen to Webcast Investor Meeting at ASCO 2021 PR Newswire THOUSAND OAKS, Calif., June 1, 2021 THOUSAND OAKS, Calif., June...
Read moreTaltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study
Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study...
Read moreBIOLASE to Present at the Summer Solstice Best Ideas From the Buy Side Conference on June 2, 2021
BIOLASE to Present at the Summer Solstice Best Ideas From the Buy Side Conference on June 2, 2021 PR Newswire...
Read moreBridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery...
Read moreStealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Barth Syndrome
Stealth BioTherapeutics Receives Orphan Drug Designation from the European Medicines Agency for Elamipretide for the Treatment of Barth Syndrome PR...
Read moreCTI BioPharma Reports First Quarter 2021 Financial Results
CTI BioPharma Reports First Quarter 2021 Financial Results - NDA for Pacritinib for the Treatment of Myelofibrosis Patients with Severe...
Read moreAvantor® Acquires RIM Bio; Expands Bioproduction Footprint into China
Avantor® Acquires RIM Bio; Expands Bioproduction Footprint into China Changzhou, China, operations become Avantor's first single-use production facility in AMEA...
Read more